Table 2.
Atorvastatin |
Pravastatin |
Rosuvastatin |
|||||
Mean | SD | Mean | SD | Mean | SD | P | |
Total cholesterol, mg/dL | 239 | 56 | 240 | 58 | 219 | 38 | .004 |
LDL-C, mg/dL | 140 | 36 | 141 | 40 | 134 | 30 | .3 |
Triglyceride, mg/dL | 373 | 375 | 322 | 244 | 310 | 238 | .08 |
HDL-C, mg/dL | 38 | 10 | 40 | 14 | 40 | 12 | .1 |
BMI, kg/m2 | 27 | 5 | 27 | 6 | 26 | 5 | .3 |
AST,a U/L | 30 | 18 | 34 | 27 | 32 | 21 | .2 |
ALT,a U/L | 36 | 27 | 39 | 44 | 33 | 21 | .2 |
Creatinine,b mg/dL | 1.0 | .3 | 1.1 | .8 | 1.1 | .3 | .2 |
Glucose,c mg/dL | 105 | 49 | 106 | 51 | 106 | 53 | .9 |
NOTE. Comparisons between statins were made using 1-way analyses of variance. To convert total cholesterol, LDL-C, non-HDL-C, or HDL-C values to mmol/L, multiply by .0259. To convert triglyceride values to mmol/L, multiply by .0113. ALT alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; SD, standard deviation.
Baseline AST and ALT data available on 664 patients. Data available from a median of 2 d before starting therapy (interquartile range, 0– 21 d).
Baseline creatinine data available on 676 patients. Data available from a median of 13 d before starting therapy (interquartile range, 0– 36 d).
Baseline glucose data available on 675 patients. Data available from a median of 19 d before starting therapy (interquartile range, 0– 91 d).